VitriVax
Developing thermostable, single-shot vaccine formulations to eliminate barriers to global vaccination.
Website: https://vitrivaxbio.com/
Cover Block
Public sources
| Field | Value |
|---|---|
| Name | VitriVax |
| Tagline | Developing thermostable, single-shot vaccine formulations to eliminate barriers to global vaccination. [VitriVax] |
| Headquarters | Boulder, United States [Crunchbase] |
| Founded | 2014 [Crunchbase] |
| Stage | Series C [Axios, November 2026] |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout [Startup Intros] |
| Funding Label | $100M+ |
| Total Disclosed Funding | ~$114,150,000 [Axios, November 2026] [Fierce Biotech, October 2025] [Business Wire, July 2023] [LinkedIn] [Tracxn] |
Links
Public sources
- Website: https://vitrivaxbio.com/
- LinkedIn: https://www.linkedin.com/company/vitrivax
Executive Summary
PUBLIC VitriVax develops vaccine formulations intended to make shots thermostable and potentially condense multi-dose regimens into a single administration, and it merits investor attention now because it closed an $87 million Series C in November 2026 to move its Lyme disease program into first-in-human testing [Axios, November 2026] [BioWorld / FirstWord Pharma, November 2026]. The company was founded in 2014 in Boulder and traces its origins to University of Colorado Boulder research, with public sources describing it as a spinout based on work from Robert Garcea and Ted W. Randolph [Startup Intros] [Crunchbase].
Its technical claim rests on the ALTA platform, which a 2026 review describes as combining spray drying in a sugar matrix with atomic layer deposition to control in vivo release, while company materials position the approach as a way to reduce cold-chain dependence and support single-shot vaccination schedules [Frontiers in Immunology, 2026] [VitriVax]. Public reporting also ties the platform to a lead Lyme disease vaccine candidate that management intends to advance into the clinic, which gives investors a nearer-term readout than platform stories usually offer at this stage [Axios, November 2026] [Pulse2].
The founding bench is more academic than commercial, which is consistent with the company’s spinout profile: Garcea is listed by the University of Colorado Boulder as Professor Emeritus in Molecular, Cellular & Developmental Biology, and current leadership includes CEO Romulo Colindres according to LinkedIn and Axios reporting [University of Colorado Boulder] [LinkedIn] [Axios, November 2026]. That mix matters because the technical ambition is high, but the next 12 to 18 months will test whether the company can translate formulation science into clinical execution and, eventually, partnerable product economics.
Funding support has been substantial and diversified. Public disclosures point to roughly $114.15 million in total disclosed capital across venture rounds and grants, including a $17.25 million Series B in 2025, a $29 million Defense Threat Reduction Agency award in 2023, CEPI support, and the 2026 Series C led by F-Prime, with participation from NEA, RA Capital Management, Sanofi Ventures, Eli Lilly and Company, and earlier backing from Adjuvant Capital [Fierce Biotech, October 2025] [Business Wire, July 2023] [Axios, November 2026].
The business model appears to be B2B and partnership-led rather than commercial sales led at this point, with the company pairing wholly owned vaccine candidates with strategic and global health relationships [VitriVax] [Morningstar / Business Wire, November 2026]. The practical watch items are straightforward: evidence that ALTA performs in humans rather than preclinical settings, whether the Lyme candidate reaches first-in-human study on the stated timeline, and whether non-dilutive and strategic support continues to validate demand for thermostable, simplified vaccine delivery [BioWorld / FirstWord Pharma, November 2026] [CEPI] [Business Wire, July 2023].
Lightly corroborated -- Core financing and leadership points are corroborated by Axios, Fierce Biotech, Business Wire and LinkedIn, but key product-performance claims still rely partly on company materials and limited secondary coverage.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series C |
| Business Model | B2B |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | $100M+ total disclosed, approximately $114.15M [Axios, November 2026] [Fierce Biotech, October 2025] [Business Wire, July 2023] |
How the Company Got Here
PUBLIC
VitriVax traces back to a university research setting rather than a commercial vaccine roll-up, which matters because the company is still best understood as a platform spinout building around formulation science. The company was founded in 2014, is headquartered in Boulder, Colorado, and describes its mission as eliminating barriers to global vaccination through thermostable, single-shot vaccine formulations [Crunchbase] [VitriVax]. Startup Intros, a secondary company profile, describes VitriVax as a spinout from the University of Colorado Boulder based on research in the labs of Robert Garcea and Ted W. Randolph, but that spinout history is not stated in the two preferred sources for this section, so the public record here is kept to the company and database descriptions [Crunchbase] [VitriVax].
The public chronology is concise but coherent. Crunchbase lists the company as founded in 2014 and based in Boulder, while the company website frames VitriVax around the same core proposition, reducing cold-chain and dosing barriers through its vaccine formulation platform [Crunchbase] [VitriVax]. By late 2026, the company had also reached Series C stage according to Crunchbase, which places it beyond the earliest research-spinout phase even if the public operating history between founding and scale-up remains lightly documented in state-style records available here [Crunchbase].
Independently corroborated -- Confirmed by Crunchbase and the company website.
Product and Technology
MIXED
The product story is narrower, and more interesting, than a generic vaccine-platform pitch. VitriVax describes ALTA, short for Atomic Layering Thermostable Antigen and Adjuvant, as a formulation approach intended to make vaccines more temperature-stable and to compress multi-dose regimens into a single administration [VitriVax]. Public third-party coverage links that platform directly to the company’s lead Lyme disease vaccine program and to its stated goal of moving that candidate into first-in-human testing following the November 2026 financing [Axios, November 2026] [BioWorld / FirstWord Pharma, November 2026].
The technical mechanism is at least partly described in the scientific literature, which matters because much of the surrounding company coverage is financing-driven. A 2026 Frontiers in Immunology article describes ALTA as combining spray drying to stabilize antigens in a sugar matrix with atomic layer deposition coating to control release timing in vivo [Frontiers in Immunology, 2026]. Separately, Pharmaceutical Technology reported that vaccines formulated with the platform can remain stable at temperatures up to 70°C for months, though that operating claim should still be read as platform-level reporting rather than product-by-product clinical validation [Pharmaceutical Technology].
VitriVax’s public materials also show where the platform may be tested beyond Lyme. CEPI said researchers at the company would explore adapting Serum Institute of India’s three-dose rabies vaccine, RabiVax-S, onto ALTA for single-shot delivery with controlled release, which indicates at least one externally named use case for the formulation technology outside a wholly owned asset [CEPI]. That said, the public record here is stronger on formulation intent and funding support than on human data, regulatory progress, or commercial deployment, so the core diligence question remains whether the thermostability and release-control claims translate consistently across antigens and adjuvants rather than in selected proof points [VitriVax] [CEPI] [BioWorld / FirstWord Pharma, November 2026].
Lightly corroborated -- Product descriptions are corroborated across the company website, scientific literature, and named press coverage, but several performance claims remain company-led or single-source.
Where the Demand Sits
PUBLIC
The market matters now because vaccine developers and funders are again putting capital behind manufacturing resilience and simplified dosing, two problems that sit upstream of product efficacy and downstream of public-health adoption [Axios, November 2026] [Business Wire, July 2023] [CEPI].
The public record does not provide a cited TAM, SAM, or SOM for VitriVax itself, so the cleaner approach is to frame the addressable demand through adjacent markets that the company explicitly touches: vaccine development, cold-chain dependent biologics distribution, and global immunization programs seeking dose simplification [VitriVax] [CEPI] [Business Wire, July 2023]. VitriVax describes its ALTA platform as a way to make vaccines thermostable and to incorporate booster timing into a single administration, which positions it at the intersection of formulation technology and vaccine program design rather than as a conventional single-asset biotech alone [VitriVax] [Frontiers in Immunology, 2026]. That distinction matters commercially, because a platform that reduces storage constraints or repeat dosing can, at least in principle, sell into both proprietary pipeline programs and external partnership work, though the current public evidence is stronger on funding support than on customer adoption [Morningstar / Business Wire, November 2026] [Fierce Biotech, October 2025].
Demand signals in the cited record are indirect but real. The strongest are non-dilutive awards tied to biodefense and epidemic preparedness, including a $29 million five-year contract from the Defense Threat Reduction Agency in July 2023 and a reported $5 million CEPI grant to accelerate single-administration, thermostable vaccines [Business Wire, July 2023] [LinkedIn]. Those are not commercial purchase orders, but they do show that government and global-health buyers are willing to fund the underlying problem set, namely cold-chain reduction, field deployability, and better completion of multi-dose regimens [Business Wire, July 2023] [CEPI]. The 2026 Series C also suggests that private investors see enough category momentum to fund a transition from platform promise to first-in-human testing in Lyme disease, which is a more demanding proof point than preclinical platform financing alone [Axios, November 2026] [BioWorld / FirstWord Pharma, November 2026].
Adjacent markets widen the opportunity, even if they also complicate benchmarking. VitriVax's public materials and CEPI-linked work imply relevance to travel vaccines, endemic infectious-disease programs, biodefense stockpiling, and contract formulation support for vaccine manufacturers that need longer shelf life or less refrigeration dependence [VitriVax] [CEPI] [Business Wire, July 2023]. Substitute approaches would include conventional cold-chain logistics, reformulation work inside large pharma, and alternative delivery technologies that aim to improve adherence without changing vaccine antigens themselves [Frontiers in Immunology, 2026]. For investors, the implication is that market demand may exist even if any single vaccine indication proves narrow, but the route to capture still depends on whether VitriVax can translate platform attributes into regulated products or partnerable formulation outcomes [Morningstar / Business Wire, November 2026] [VitriVax].
Regulatory and macro forces appear supportive, though not uniformly so. Public-health agencies and preparedness funders increasingly value shelf-life extension, domestic manufacturing readiness, and distribution models that can tolerate infrastructure constraints, which helps explain awards from DTRA and support from CEPI and the Gates Foundation cited in financing coverage [Business Wire, July 2023] [Fierce Biotech, October 2025] [Morningstar / Business Wire, November 2026]. The counterweight is that vaccine formulation changes can create additional development and regulatory work, especially when the commercial claim is not merely stability but altered dosing cadence or controlled in vivo release [Frontiers in Immunology, 2026]. In practice, that means the market can be large in public-health terms while remaining slow to monetize, because procurement interest does not eliminate the need for clinical evidence, manufacturability, and indication-specific approval pathways [BioWorld / FirstWord Pharma, November 2026] [CEPI].
| Cited market signal | Relevance to market demand | Source |
|---|---|---|
| $29M five-year DTRA contract | Indicates U.S. biodefense demand for vaccine-related formulation or preparedness capabilities | [Business Wire, July 2023] |
| $5M CEPI grant | Indicates epidemic-preparedness demand for single-administration, thermostable vaccines | [LinkedIn] |
| $9.9M Gates Foundation grant | Indicates philanthropic demand tied to manufacturing and Phase 1 readiness | [Fierce Biotech, October 2025] |
| $87M Series C | Indicates private-capital appetite for advancing the platform into clinical testing | [Axios, November 2026] |
Taken together, the table does not size the market, but it does show a consistent pattern: preparedness institutions and specialist investors are paying to reduce storage and dosing friction in vaccines. That is a narrower claim than broad market validation, though it is enough to support continued diligence on category demand.
Lightly corroborated -- This section relies on named public sources for funding and grant signals, but no third-party TAM/SAM/SOM dataset was available and several market inferences are drawn from adjacent public-health and financing evidence.
Competitive Landscape
Market structure
MIXED VitriVax is positioned less against a single named peer than against the operating assumptions of the vaccine industry itself, namely cold-chain dependence and multi-dose scheduling, both of which its ALTA formulation platform is designed to reduce [VitriVax] [Frontiers in Immunology, 2026].
The competitive map is therefore best read in segments rather than logo against logo. In the first segment are incumbent vaccine developers, which control antigen discovery, clinical development, manufacturing scale, and commercial channels. VitriVax does not appear, on the public record, to match those incumbents on distribution or late-stage clinical infrastructure; its pitch is to sit upstream of that bottleneck by improving how vaccines are formulated and delivered [VitriVax] [Axios, November 2026].
A second segment is global-health and government-backed vaccine development, where procurement constraints and field logistics matter almost as much as immunogenicity. Here the evidence is more concrete. VitriVax has attracted non-dilutive support from the Defense Threat Reduction Agency and CEPI, and later drew capital from specialist healthcare investors and strategic backers including Sanofi Ventures and Eli Lilly and Company, which suggests its formulation thesis resonates with parties that understand both deployment friction and regulated biologics development [Business Wire, July 2023] [LinkedIn] [Axios, November 2026] [Morningstar / Business Wire, November 2026].
A third segment is adjacent substitutes. The clearest substitute is not a named startup in the source set, but conventional refrigerated, multi-dose vaccines supported by established cold-chain distribution. Those alternatives are operationally entrenched, clinically familiar, and already embedded in procurement systems. That matters because VitriVax is not only competing to prove a product candidate, it is also competing to change a workflow that health systems already know how to run [VitriVax] [BioWorld / FirstWord Pharma, November 2026].
Sources of advantage and exposure
MIXED The company's edge today appears to rest on technical specialization, mission-aligned capital, and fit with public-sector use cases. Public materials describe ALTA as a process that combines spray drying to stabilize antigens in a sugar matrix with atomic layer deposition for temporal control over in vivo release, a formulation approach that is at least directionally differentiated from standard storage-and-delivery methods [Frontiers in Immunology, 2026]. The University of Colorado Boulder roots also matter, because the company emerged from research in the labs of Robert Garcea and Ted W. Randolph, giving it a clearer scientific origin than many platform claims that enter the market through financing announcements first and validation later [Startup Intros] [University of Colorado Boulder, retrieved 2026].
That edge is promising, but only partly durable on public evidence. Capital support from Adjuvant Capital, RA Capital Management, F-Prime, NEA, Sanofi Ventures, Eli Lilly and Company, CEPI, and the Gates Foundation improves staying power and may widen the set of partnership paths available to the company [Fierce Biotech, October 2025] [Axios, November 2026] [Morningstar / Business Wire, November 2026]. Still, public sources do not yet show commercial deployments, approved products, or named formulation customers, so the defensibility remains pre-commercial and dependent on translational execution rather than installed market power [Axios, November 2026] [VitriVax].
The exposure is equally clear. Large vaccine companies already own the channels that matter most once a program moves beyond preclinical promise: clinical operations, manufacturing validation, regulatory affairs, and global procurement. If VitriVax's advantage is primarily formulation-layer improvement, incumbents or partners with stronger antigen portfolios and commercial infrastructure could capture more of the downstream economics even if the underlying delivery concept proves sound [BioWorld / FirstWord Pharma, November 2026] [Morningstar / Business Wire, November 2026].
Competitive scenario over the next 18 months
MIXED The most plausible near-term competitive scenario is not share capture from a named startup, because the source set does not identify one, but a sorting between platforms that can cross into human data and those that remain scientifically interesting but commercially uncommitted. On that basis, VitriVax is a potential winner if its planned first-in-human Lyme program advances on schedule and shows that single-administration, thermostable formulation can survive the transition from platform narrative to clinical evidence [Axios, November 2026] [Pulse2] [Allsci].
The more likely loser in that scenario is the legacy multi-dose, cold-chain-dependent product architecture for indications where adherence and field logistics are meaningful constraints. That is not a corporate loser so much as a design loser. If human data fail to validate the release-control or immunogenicity thesis, however, the reverse would hold and incumbent vaccine development models would remain the default winner because they already control the channels, budgets, and regulatory muscle that new formulation platforms eventually need to access [Frontiers in Immunology, 2026] [VitriVax] [Business Wire, July 2023].
Lightly corroborated -- Competitive framing is grounded in public company materials, Frontiers in Immunology, Axios, and financing coverage, but the source set names no direct startup competitors and provides limited independent evidence on commercial adoption.
Opportunity
PUBLIC
If VitriVax executes, the prize is not simply one vaccine asset, it is a formulation platform that could remove two of the most persistent bottlenecks in immunization, cold-chain dependence and multi-dose adherence, across both commercial and public-health channels [VitriVax] [Frontiers in Immunology, 2026] [Axios, November 2026].
The headline opportunity rests on a platform claim that is unusually legible in business terms. VitriVax is developing ALTA, a formulation approach that combines spray drying with atomic layer deposition to stabilize vaccine components and control in vivo release, with the stated goal of enabling thermostable, single-administration vaccines [Frontiers in Immunology, 2026] [VitriVax]. That matters because the company is not positioning ALTA only as an internal R&D tool. Public materials and financing coverage point to a model that combines wholly owned programs, including a Lyme disease candidate headed toward first-in-human study, with strategic and global-health partnerships, which creates more than one route to scale if the underlying formulation approach works in humans [Morningstar / Business Wire, November 2026] [BioWorld / FirstWord Pharma, November 2026] [CEPI].
The financing history makes that upside reachable rather than purely theoretical. VitriVax has attracted support from specialist biotech investors including F-Prime, NEA, RA Capital Management, Adjuvant Capital, and Sanofi Ventures, along with non-dilutive backing from DTRA, CEPI, and the Gates Foundation across separate disclosures from 2023 to 2026 [Axios, November 2026] [Fierce Biotech, October 2025] [Business Wire, July 2023] [LinkedIn] [Tracxn]. Investors should still treat efficacy and manufacturability as open questions, but this is already financed like a company trying to prove a repeatable vaccine-enablement platform, not only a single preclinical program [Morningstar / Business Wire, November 2026] [Yahoo Finance / Business Wire, October 2025].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform validation via Lyme | The Lyme candidate reaches the clinic and becomes the proof point that ALTA can carry a wholly owned asset into human testing, opening the door to follow-on fundraising, partnering, or broader platform adoption. | First-in-human trial initiation for the Lyme program [Axios, November 2026] [BioWorld / FirstWord Pharma, November 2026] | The November 2026 Series C was raised specifically to advance the Lyme candidate into the clinic, suggesting investors financed a near-term validation step rather than a distant concept [Morningstar / Business Wire, November 2026] [Axios, November 2026]. |
| Become a formulation partner for vaccine incumbents | Large vaccine developers use ALTA to reformulate existing or pipeline products for thermostability or controlled booster release, turning VitriVax into a picks-and-shovels supplier to the sector. | A disclosed strategic partnership or development agreement with a pharmaceutical manufacturer, particularly given existing investor overlap with major industry players [Morningstar / Business Wire, November 2026] | The company already frames its model around strategic partnerships, and its cap table includes Sanofi Ventures and participation from Eli Lilly and Company, which does not prove commercial use but does place the company near potential enterprise counterparties [VitriVax] [Morningstar / Business Wire, November 2026]. |
| Win global-health procurement pathways | ALTA is adopted in programs where heat stability and single-visit administration have outsized value, such as outbreak response or hard-to-reach populations, creating non-dilutive demand and validation. | Progress on CEPI-backed work, including the publicly referenced rabies collaboration involving Serum Institute of India [CEPI] | CEPI has supported VitriVax and publicly described work to adapt Serum Institute of India's three-dose rabies vaccine for single-shot delivery using ALTA, which is a concrete use case aligned with the platform's stated strengths [CEPI] [LinkedIn]. |
The compounding mechanism, if it appears, would come from technical reuse and buyer familiarity rather than a consumer network effect. A successful first program could validate ALTA's core claim that one manufacturing and formulation approach can improve thermal stability and dosing convenience across multiple antigens and adjuvants, which would lower the burden of selling each subsequent program from first principles [VitriVax] [Frontiers in Immunology, 2026]. In parallel, non-dilutive support from DTRA, CEPI, and the Gates Foundation suggests external institutions already see platform-level relevance in the problem set, which can matter in vaccines because procurement, funding, and regulatory pathways often reward de-risked delivery formats as much as novel biology [Business Wire, July 2023] [Fierce Biotech, October 2025] [LinkedIn].
The size of the win is easiest to frame as a scenario, not a forecast. If VitriVax proves that ALTA can support one internal clinical asset and wins even a small number of external formulation partnerships, the company could start to resemble a platform biotech with both asset and enablement value, rather than a single-asset vaccine developer. No credible public comparable valuation was provided in the source set, so attaching a precise outcome range would overstate the evidence. What can be said on the record is narrower and still material: more than $114 million in disclosed funding and grants has already been assembled around the thesis that thermostable, single-shot vaccine delivery can support a venture-scale company, and the upside case is that human data turns that financing base into a durable platform business with strategic value to vaccine manufacturers and global-health funders alike [Axios, November 2026] [Fierce Biotech, October 2025] [Business Wire, July 2023] [Tracxn].
Lightly corroborated -- This section relies on multiple public sources for financing, leadership, and partnership support, but several core product and platform claims remain supported primarily by company materials or a single technical source.
Sources
Public sources
[VitriVax] VitriVax: Eliminating barriers to global vaccination | https://vitrivaxbio.com/
[Crunchbase] VitriVax - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/vitrivax
[Axios, November 2026] Exclusive: VitriVax raises $87M Series C for Lyme disease vaccine | https://www.axios.com/2026/11/18/vitrivax-series-c-lyme-disease-vaccine
[Fierce Biotech, October 2025] Fierce Biotech / fundraising coverage, October 2025 | https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25-vitrivax-raises-1725-million
[Business Wire, July 2023] VitriVax Awarded $29M Contract to Develop Thermostable Single-Shot Vaccines Against Emerging Biological Threats | https://www.businesswire.com/news/home/20230711065994/en/VitriVax-Awarded-29M-Contract-to-Develop-Thermostable-Single-Shot-Vaccines-Against-Emerging-Biological-Threats
[LinkedIn] VitriVax | LinkedIn | https://www.linkedin.com/company/vitrivax
[Tracxn] VitriVax - Funding and Investors | https://tracxn.com/d/companies/vitrivax/__0w7t7f7O1hIuW3Y6A9fV6xv9xjN4GQJp8p3YyQx1m6A
[BioWorld / FirstWord Pharma, November 2026] VitriVax raises $87M to advance single-dose Lyme disease vaccine | https://www.bioworld.com/articles/556082-vitrivax-raises-87m-to-advance-single-dose-lyme-disease-vaccine
[Startup Intros] VitriVax: Funding, Team & Investors | Startup Intros | https://startupintros.com/orgs/vitrivax
[Frontiers in Immunology, 2026] Frontiers in Immunology article describing ALTA formulation approach | https://www.frontiersin.org/
[Pulse2] VitriVax: Thermostable Vaccine Company Raises $87 Million (Series C) | https://pulse2.com/vitrivax-thermostable-vaccine-company-raises-87-million-series-c/
[University of Colorado Boulder] Robert Garcea | University of Colorado Boulder | https://www.colorado.edu/lab/garcea/
[Morningstar / Business Wire, November 2026] VitriVax Announces $87 Million Series C Financing to Advance Lyme Disease Vaccine Candidate into the Clinic and Expand Pipeline | https://www.morningstar.com/news/business-wire/20261118005470/vitrivax-announces-87-million-series-c-financing-to-advance-lyme-disease-vaccine-candidate-into-the-clinic-and-expand-pipeline
[CEPI] CEPI backs VitriVax to develop single-shot thermostable rabies vaccine with Serum Institute of India | https://cepi.net/news_cepi/cepi-backs-vitrivax-to-develop-single-shot-thermostable-rabies-vaccine-with-serum-institute-of-india/
[Pharmaceutical Technology] VitriVax's thermostable vaccine formulations can be kept at temperatures as high as 70° Celsius for months | https://www.pharmaceutical-technology.com/
[Allsci] VitriVax plans to advance its preclinical single-dose Lyme disease vaccine candidate into a Phase I trial | https://allsci.com/
[Yahoo Finance / Business Wire, October 2025] VitriVax Raises $17.25 Million Series B Financing to Advance Vaccine Formulation Platform | https://finance.yahoo.com/news/vitrivax-raises-17-25-million-130000000.html
Articles about VitriVax
- VitriVax's 70°C Vaccine Platform Is Chasing a Lyme Disease First — The Boulder biotech has raised over $114 million and secured non-dilutive grants to prove its thermostable, single-dose ALTA platform can work in humans.